American Made Pharmaceuticals Act of 2022
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Apr 5, 2022)
American Made Pharmaceuticals Act of 2022
This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).
The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.
What just happenedApr 6, 2022
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseApr 5, 2022
- Apr 6, 2022Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Apr 5, 2022IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Apr 5, 2022IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Apr 5, 2022IntroReferralIntro-H
Introduced in House
- Apr 5, 2022IntroReferral1000
Introduced in House